ClinicalTrials.gg
RecruitingNCT00837122Updated Nov 3, 2026

Genetics of Type 2 Diabetes in West Africans

An observational study in Hypertension and Diabetes, sponsored by National Human Genome Research Institute (NHGRI). Recruiting at 5 sites in 2 countries. Open to participants aged 18 Years to 120 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by National Human Genome Research Institute (NHGRI) · Observational

How we know

From the registry’s dates

  • Started Feb 2009; still recruiting 17 years 9 months later.
Updated Nov 3, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
10,000
Ages
18 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 31 studies in Hypertension with a site in Nigeria — 11 open to participants now, 14 under way, none of them phase 3. Hypertension · Nigeria.

Planned enrollment
2nd of 10
10,000 · median 2,915
Started
2009
with 1 other
Observational
10 of 31
5 open now
Registered
2nd of 31
by date

Among the 31 studies in Hypertension with a site in Nigeria, this one is the 2nd largest by planned enrollment of the 10 observational ones that give a count, is one of 2 that started in 2009, is one of 10 observational ones, and was the 2nd registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

11 of the 31 studies in Hypertension with a site in Nigeria are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Nigeria have not opened yet or have stopped. Only those recruiting at a site in Nigeria →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years to 120 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Hypertension with a site in Nigeria, or all of them as a file.
02

Study summary

Background:

  • Type 2 diabetes (T2D) and associated complications are major contributors to the global disease burden. T2D is already a major health threat in populations in developed countries and is rapidly taking hold in the developing world.
  • It is believed that understanding the complex interplay between genetic and lifestyle characteristics in the etiology of T2D and related complications will lead to the development of better preventive and therapeutic strategies. In Addition, the results of this project will facilitate our understanding of causes of diabetes in African Americans, other US and world populations

Objectives:

  • To conduct a genome-wide association study (GWAS) to identify susceptibility genetic variants for diabetes among the Yoruba people in Ibadan, Nigeria.
  • To enroll and examine 300 unrelated cases of T2D and 300 ethnicity-matched Yoruba controls.
  • To conduct resequencing of positional candidate gene/loci to identify likely functional variants in a subset of the cohort.
  • To conduct replication studies of the top-100 scoring variants in three independent African and European ancestry samples.
  • To investigate whether diabetes-associated variants discovered in European populations increase diabetes risk in West Africans.

Eligibility:

  • Patients 18 years of age with confirmed T2D who are newly diagnosed or on treatment of Yoruba ethnicity in Ibadan, Nigeria. Control subjects are nondiabetics ethnically matched to patients.

Design:

  • The study design for both patients and controls consists of the following steps:
  • Discuss informed consent process and obtain signed informed consent form. Informed consent will be administered by trained clinic staff.
  • Assign study ID (barcode)
  • Administer questionnaires
  • Obtain spot urine sample
  • Measure blood pressure
  • Obtain anthropometric measurements including body composition
  • Perform finger prick for blood glucose level
  • Obtain venous blood samples
  • Perform eye examination
  • On the following day, perform confirmatory blood glucose for the small subset of participants requiring confirmation of previous test result DNA extraction of stored samples will be done at either the National Institutes of Health or the laboratory in Nigeria.
  • GWAS will be conducted using publicly available software packages.
Read the detailed description

Study Description:

This protocol is designed to study the genetic basis of Type 2 Diabetes (T2D) and related conditions in Africa.

Objectives:

Primary Objective: To conduct genetic association studies of T2D, T2D complications, and related traits in Africans of diverse ethnic groups

Secondary Objectives:

  • To investigate the contribution of gene x environment interactions in T2D risk and in influencing related traits
  • To develop a large-scale genetic epidemiological resource for the replication of findings in other studies of related traits
  • To conduct trans-ethnic fine-mapping
  • To describe the study population epidemiologically in terms of cardiometabolic traits and prevalence of related conditions
  • To conduct population genetic analyses to describe population history and to develop statistical techniques appropriate for genetic analyses of African ancestry individuals
  • To conduct deep phenotyping to facilitate additional research questions related to cardiometabolic traits and for follow-up previous findings

Endpoints:

Primary Endpoint: T2D

Secondary Endpoints: T2D Complications, Hypertension, Obesity, Dyslipidemia, Metabolic Syndrome, Chronic Kidney Disease, and other cardiometabolic traits

03

Conditions studied

  • Hypertension
  • Diabetes

Keywords

  • African
  • Natural History
04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients with confirmed T2D who are newly diagnosed or on treatment and those without T2D (ethnically matched) in Ibadan, Nigeria

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

As our primary interest is in T2D, it is important to exclude individuals who may have diabetes of another etiology. Elevated blood glucose in individuals 25 years old or younger is unlikely (in West Africa) to result from T2D and may reflect Type 1 Diabetes. Therefore, only individuals older than 25 years will be included in this study.

We are seeking to enroll persons without T2D or with previously or newly diagnosed T2D. Previously diagnosed cases will be determined by self-report of being treated with oral medication or insulin. Newly diagnosed cases will be determined by fasting blood glucose value >= 126 mg/dl on more than one occasion. Individuals who have elevated blood glucose during their initial reading will be asked to return to the study site for a second test. If this test also has a fasting blood glucose value >= 126 mg/dl, then they will be considered a new case. The control group will be individuals with no report of T2D diagnosis and fasting plasma glucose (FPG)\< 126 mg/dl.

Only unrelated individuals will be included in this phase of the study to avoid confounding genetic association studies by relatedness in the study population.

Exclusion criteria

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

  • Incarceration.
  • Lack capacity to consent to research participation.
  • Pregnancy.
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
10,000 participants (estimated)

Groups and cohorts

  • Control

    Control subjects are nondiabetics ethnically matched to patients

  • T2D

    Patients with confirmed T2D who are newly diagnosed or on treatment in Ibadan, Nigeria

06

What researchers measure

Primary outcomes

  1. I

    In a subset of participants, to investigate the relationship between diets, gut microbiota, and T2D/related traits.

    Time frame: ongoing

  2. H

    To investigate whether hemoglobin A1c (HbA1c) as an indicator of blood glucose control over time is reliable in the presence of the sickle cell trait (HbS), a common hemoglobinopathy in West Africa. The association between HbA1c repeated measures and changes in T2D-related traits over time will be evaluated. We will also evaluate if there is a systematic difference (bias) in the estimation of A1c in carriers of the sickle trait and non-carriers in persons with and without diabetes.

    Time frame: ongoing

  3. G

    g- In a subset of participants, to investigate key tissues in the pathophysiology of T2D, we will study differences in the gene expression of skeletal muscle and adipose tissue in lean and obese individuals with and without T2D (n=100, Biopsy Substudy).

    Time frame: ongoing

  4. F

    f- To conduct population genetic analyses to describe population history and to develop statistical techniques appropriate for genetic analysis of African ancestry individuals.

    Time frame: ongoing

  5. E

    e-To describe these individuals epidemiologically in terms of metabolic traits and the prevalence of relevant conditions, as, for some traits, this may be the first large-scale epidemiological, population-based study of Africans with the appropriate data for such description.

    Time frame: ongoing

  6. D

    d- To conduct trans-ethnic fine mapping to determine whether the reduced LD across the genome in African ancestry individuals can refine the region of interest around genetic associations discovered in populations of non-African ancestry. To conduct candidate gene resequencing, Whole Genome Sequencing (WGS), or Whole Exome Sequencing (WES), as funding allows, in participants with metabolic profiles of interest. For instance, individuals will be selected who have extreme values for serum lipids for WES. Variants identified by this resequencing will be genotyped in the larger study population for association analysis.

    Time frame: ongoing

  7. C

    c- To develop a large-scale genetic epidemiological resource for the replication of findings in other studies of related traits in African ancestry and non-African ancestry individuals.

    Time frame: ongoing

  8. B

    b- To investigate the contribution of gene x environment interactions in T2D risk and in influencing related traits. These investigations may be conducted on either a hypothesis-driven, locus-specific manner or agnostically, i.e. genome-wide. Environmental variants to be considered include lifestyle factors (e.g. diet, measured by food frequency questionnaires (FFQ), socioeconomic measures, and medications taken.

    Time frame: ongoing

  9. A

    a- To conduct genetic association studies of T2D and related traits (including blood pressure, serum lipids, blood glucose, adiposity) in West Africans of diverse ethnic groups. Approaches will include genome-wide association studies (including exome chip data) and candidate gene/loci association analyses.

    Time frame: ongoing

07

Study locations

1 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Extensive review of the consents related to this protocol by the NHGRI IRB was conducted and it was determined that because the initial consent process did not address sharing of participants' data and the related risks and the carefully established rapport and trust with African populations and collaborators, it would not be appropriate to share participant's data. A memorandum to this effect can be provided, if necessary. We will continue to be open to making the data available through collaboration, a use of the data that was described in initial consent forms.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026

Started Feb 2009 (actual).

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2009
First posted
Feb 5, 2009
StartActual
Feb 3, 2009
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Completed→Recruiting
changed Nov 3, 2026
Sites
5 sites changed recruiting status (4 now completed, 1 now recruiting)
Show 5 sites
  • University of Ghana · Accra, Ghanano status→Completed
  • University of Science and Tech · Kumasi, Ghanano status→Completed
  • University of Nigeria · Enugu, Nigeriano status→Completed
  • University of Ibadan · Ibadan, Nigeriano status→Recruiting
  • University of Lagos · Lagos, Nigeriano status→Completed
Nov 3, 2026
Enrollment
7418 (actual)→10000 (estimated)
Nov 3, 2026
Contact
Study contact now listed: added f•••@mail.nih.gov · •••2302; added r•••@mail.nih.gov · •••2303. See the current contact
Nov 3, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • University of Ibadan · Ibadan, NigeriaContact added c•••@yahoo.com · •••6116
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Completed→Recruiting
    5 sites changed recruiting status (4 now completed, 1 now recruiting)
    Show 5 sites
    • University of Ghana · Accra, Ghanano status→Completed
    • University of Science and Tech · Kumasi, Ghanano status→Completed
    • University of Nigeria · Enugu, Nigeriano status→Completed
    • University of Ibadan · Ibadan, Nigeriano status→Recruiting
    • University of Lagos · Lagos, Nigeriano status→Completed
    Enrollment 7418 (actual)→10000 (estimated)
    Contact Study contact now listed: added f•••@mail.nih.gov · •••2302; added r•••@mail.nih.gov · •••2303. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • University of Ibadan · Ibadan, NigeriaContact added c•••@yahoo.com · •••6116
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT00837122
Responsible party
Sponsor
First posted
Feb 5, 2009
Start date
Feb 3, 2009
Last update
Nov 3, 2026

Study contacts

Shirley T Freeman
Contact
freemansh@mail.nih.gov
(301) 451-2302
Charles N Rotimi, M.D.
Contact
rotimic@mail.nih.gov
(301) 451-2303
Charles N Rotimi, M.D.
principal investigator · National Human Genome Research Institute (NHGRI)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion